Gynesonics, Inc.

Gynesonics is a medical device company focused on advancing women's healthcare through minimally invasive solutions. Their primary product, the Sonata System, is the world's first and only intrauterine fibroid ablation system that combines ultrasound guidance with targeted radiofrequency energy. This incisionless procedure provides a safe and effective alternative to surgery for women experiencing symptoms related to uterine fibroids, such as heavy menstrual bleeding.

Gynesonics prioritizes innovation, teamwork, respect, accountability, and excellence. The company has received multiple awards recognizing its cutting-edge technology and commitment to improving women's lives. They are dedicated to expanding access to the Sonata Treatment globally, with a focus on research, development, and clinical studies to further refine their technology and ensure patient safety and effectiveness.

Gynesonics is dedicated to advancing women's health by developing minimally invasive, transcervical, uterus-preserving technologies for both diagnostic and therapeutic applications. They are committed to providing women with safe and effective incisionless alternatives to invasive surgical procedures like hysterectomy and myomectomy, particularly for the treatment of symptomatic uterine fibroids. Their mission centers around improving women's lives by offering innovative solutions that minimize discomfort and recovery time while preserving reproductive capabilities.

Gynesonics fosters a culture centered on innovation, teamwork, respect, and accountability. Their mission of advancing women's health drives a collaborative and results-oriented environment where employees value differing perspectives and take responsibility for achieving excellence.